Merck Drug Works: Vytorin Study Proves Successful

By | November 17, 2014

Scalper1 News

Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. “In Improve-It, patients taking the LDL-cholesterol-lowering medicine Vytorin — which combines simvastatin with the nonstatin Zetia (ezetimibe) — experienced significantly fewer major cardiovascular events Scalper1 News

Scalper1 News